Copertina

Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14‐Year Experience of an Academic Center

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Danai Dima, Utkarsh Goel, Fauzia Ullah, Beth Faiman, Diana Basali, Sandra Mazzoni, Louis S. Williams, Christy Samaras, Jason Valent, Faiz Anwer, Jack Khouri, Shahzad Raza
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Hematological Oncology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy
di: Danai Dima, et al.
Pubblicazione: (2024)

Evaluating ChatGPT as an educational resource for patients with multiple myeloma: A preliminary investigation
di: Ludovic Saba, et al.
Pubblicazione: (2024)

Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study
di: Pallawi Torka, et al.
Pubblicazione: (2025)

883 | SILTUXIMAB IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: REAL‐WORLD EXPERIENCE FROM ROMANIA AND GREECE
di: C. Tomuleasa, et al.
Pubblicazione: (2025)

Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients
di: Kaitlin Annunzio, et al.
Pubblicazione: (2024)

Current management of non‐amyloidosis monoclonal gammopathy of renal significance: Clinical features, treatment selections, responses and renal outcomes
di: Daniel Cancilla, et al.
Pubblicazione: (2025)

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma
di: Juliette Penichoux, et al.
Pubblicazione: (2025)

Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis
di: Maria Livia Del Giudice, et al.
Pubblicazione: (2024)

Upregulated miR‐29a‐3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1
di: Tengfei Shi, et al.
Pubblicazione: (2025)

Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma
di: Akihiko Izumi, et al.
Pubblicazione: (2025)

Identifying Clones in Myelodysplastic Syndromes by Using Single‐Cell RNA Sequencing
di: Roy Pollak, et al.
Pubblicazione: (2026)

444 | A PHASE 1 STUDY OF SGR‐1505, AN ORAL, POTENT MALT1 INHIBITOR FOR R/R B‐CELL MALIGNANCIES, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
di: V. Musteata, et al.
Pubblicazione: (2025)

72 | SEQUOIA 5‐YEAR FOLLOW‐UP IN ARM C: FRONTLINE ZANUBRUTINIB IN PATIENTS WITH DEL(17P) AND TREATMENT‐NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
di: C. S. Tam, et al.
Pubblicazione: (2025)

In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T‐Cell Neoplasms
di: Marie Therese Manipadam, et al.
Pubblicazione: (2024)

Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study
di: Fuli Fan, et al.
Pubblicazione: (2025)

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
di: Yutaka Shimazu, et al.
Pubblicazione: (2025)

Clonal dynamics of Richter transformation in chronic lymphocytic leukemia
di: Hanyin Wang, et al.
Pubblicazione: (2024)

598 | REDEFINING CLASSIFICATION ALGORITHM AND STAGING SYSTEM IN MARGINAL ZONE LYMPHOMA
di: C. Bommier, et al.
Pubblicazione: (2025)

Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study
di: Dong Liang, et al.
Pubblicazione: (2025)

Combining Total Metabolic Tumor Volume With Beta‐2‐Microglobulin Levels Predicts Outcomes in High‐Burden Follicular Lymphoma Patients
di: A. Zduniak, et al.
Pubblicazione: (2024)

Autoimmune Complications of Lymphoproliferative Diseases
di: Wilma Barcellini, et al.
Pubblicazione: (2025)

Current Status of Revisions to the Lugano Classification in Lymphoma
Pubblicazione: (2025)

The role of baseline 2‐[ 18 F]‐FDG‐PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis
di: Domenico Albano, et al.
Pubblicazione: (2024)

Long‐Term Follow‐Up of Chidamide With Chemotherapy in Untreated Peripheral T‐Cell Lymphoma: One Single Center Real‐World Study in China
di: Jiajie He, et al.
Pubblicazione: (2026)

Issue Information
Pubblicazione: (2026)

Differential Expression of CD79B, CD19, and PD‐L1 in de Novo and Transformed CD20‐Negative Large B‐Cell Lymphomas
di: Yuto Kaimi, et al.
Pubblicazione: (2026)

397 | ROBUST SINGLE AGENT ACTIVITY OF BI‐1808, A TUMOR NECROSIS FACTOR RECEPTOR 2 BLOCKER/DEPLETER, IN T CELL LYMPHOMA PATIENTS
di: S. Barta, et al.
Pubblicazione: (2025)

Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor‐Naïve Patients With Myelofibrosis From the Multicenter, Open‐Label, Phase 2 Study (REFINE)
di: Francesco Passamonti, et al.
Pubblicazione: (2026)

12 | IMAGING BIOMARKERS FOR THE DEFINITION OF RESPONSE IN THE GHSG HD18, GHSG HD21 AND LYSA AHL2011 TRIALS FOR ADVANCED‐STAGE HODGKIN LYMPHOMA
di: J. Ferdinandus, et al.
Pubblicazione: (2025)

15 | EARLY PET RESPONSE PREDICTS RISK OF RELAPSE AFTER 2L AXI‐CEL IN LARGE B‐CELL LYMPHOMA
di: A. Kuhnl, et al.
Pubblicazione: (2025)

301 | SOCIOECONOMIC DISPARITIES, DISEASE BURDEN AND TREATMENT INTENSITY IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA TREATED AT AN URBAN ACADEMIC CANCER CENTER
di: H. J. Cherng, et al.
Pubblicazione: (2025)

300 | DIFFUSE LARGE B‐CELL LYMPHOMA IN BRAZIL: A COMPREHENSIVE ANALYSIS OF SOCIODEMOGRAPHIC PATTERNS
di: G. Duffles, et al.
Pubblicazione: (2025)

75 | POPULATION‐WIDE INTRODUCTION OF DOSE‐ADJUSTED EPOCH‐R IN HIGH‐GRADE B‐CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS WITH DLBCL MORPHOLOGY
di: W. Alduaij, et al.
Pubblicazione: (2025)

578 | PATTERNS OF CHEMOIMMUNOTHERAPY USE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN THE US COMMUNITY SETTING
di: J. Burke, et al.
Pubblicazione: (2025)

767 | AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL FAILURE REQUIRING HEMODIALYSIS. A SINGLE‐CENTER EXPERIENCE
di: I. Kliuchagina, et al.
Pubblicazione: (2025)

610 | RELATIVE EFFICACY OF VENETOCLAX PLUS IBRUTINIB VERSUS BRUTON TYROSINE KINASE INHIBITOR MONOTHERAPY AND CHEMOIMMUNOTHERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
di: N. Ghosh, et al.
Pubblicazione: (2025)

861 | BRIDGING RADIATION THERAPY IN CAR‐T THERAPY
di: T. Li, et al.
Pubblicazione: (2025)

827 | WITHDRAWN
Pubblicazione: (2025)

826 | PET‐CT–ADAPTED TREATMENT FOR EARLY‐STAGE DIFFUSE LARGE B‐CELL LYMPHOMA WITHOUT RISK FACTORS: PRELIMINARY ANALYSIS FROM THE GATLA GROUP
di: A. Cerutti, et al.
Pubblicazione: (2025)

553 | DIGITAL TECHNOLOGY AND NATURAL LANGUAGE PROCESSING IN ACTION: EXPLORING THE BELGIAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENT POPULATION WITH THE BE‐CLLEAR STUDY
di: M. Vanderkerken, et al.
Pubblicazione: (2025)